CHARACTERIZATION OF THE ABSORPTION PHASE OF MARIJUANA SMOKING

被引:85
作者
HUESTIS, MA [1 ]
SAMPSON, AH [1 ]
HOLICKY, BJ [1 ]
HENNINGFIELD, JE [1 ]
CONE, EJ [1 ]
机构
[1] NIDA, ADDICT RES CTR, POB 5180, BALTIMORE, MD 21224 USA
关键词
D O I
10.1038/clpt.1992.100
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rapid blood collection, a paced smoking protocol and timely collection of physiologic and behavioral measures were used to characterize the absorption phase of marijuana smoking. Six healthy males smoked a single marijuana cigarette (placebo, 1.75%, or 3.55% DELTA-9-tetrahydrocannabinol) in a double-blind, randomized, Latin square study design. Rapid blood sampling with a continuous withdrawal pump allowed simultaneous collection with concurrent physiologic and behavioral measures. Mean plasma levels of 7.0 and 18.1 ng/nil DELTA-9-tetrahydrocannabinol were observed after the first inhalation of a 1.75% and 3.55% DELTA-9-tetrahydrocannabinol cigarette, respectively. Blood levels increased rapidly and peaked at 9 minutes, before initiation of the last puff sequence at 9.8 minutes. Three of six subjects reported increases in drug "liking" scores after the first puff, and all subjects responded by the second puff of a high dose cigarette. Significant increases in heart rate and diastolic blood pressure occurred shortly after peak blood levels. Previous studies have indicated that there is a substantial time delay between peak plasma levels of DELTA-9-tetrahydrocannabinol and drug-induced effects. This study showed that behavioral and physiologic effects appear concurrently or within minutes after the rapid appearance of DELTA-9-tetrahydrocannabinol in blood during marijuana smoking.
引用
收藏
页码:31 / 41
页数:11
相关论文
共 21 条
[1]  
AGURELL S, 1976, PHARM MARIHUANA, P49
[2]   BEHAVIORAL PHARMACOKINETICS OF MARIJUANA [J].
BARNETT, G ;
LICKO, V ;
THOMPSON, T .
PSYCHOPHARMACOLOGY, 1985, 85 (01) :51-56
[3]   KINETIC-STUDY OF SMOKING MARIJUANA [J].
BARNETT, G ;
CHIANG, CWN ;
PEREZREYES, M ;
OWENS, SM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (05) :495-506
[4]  
BENOWITZ N, 1990, NIDA RES MONOGR, V99
[5]   RELATIONSHIP BETWEEN PLASMA DELTA-9-TETRAHYDROCANNABINOL CONCENTRATION AND PHARMACOLOGIC EFFECTS IN MAN [J].
COCCHETTO, DM ;
OWENS, SM ;
PEREZREYES, M ;
DIGUISEPPI, S ;
MILLER, LL .
PSYCHOPHARMACOLOGY, 1981, 75 (02) :158-164
[6]  
Davis KH, 1984, CANNABINOIDS CHEM PH, P97
[7]   QUANTITATIVE MEASUREMENT OF DELTA-9-TETRAHYDROCANNABINOL AND 2 MAJOR METABOLITES IN PHYSIOLOGICAL SPECIMENS USING CAPILLARY COLUMN GAS-CHROMATOGRAPHY NEGATIVE-ION CHEMICAL IONIZATION MASS-SPECTROMETRY [J].
FOLTZ, RL ;
MCGINNIS, KM ;
CHINN, DM .
BIOMEDICAL MASS SPECTROMETRY, 1983, 10 (05) :316-323
[8]  
GRIFFITHS RR, 1982, FED PROC, V41, P234
[9]  
Haertzen C. A., 1987, METHODS ASSESSING RE, P489, DOI DOI 10.1007/978-1-4612-4812-5_24
[10]   EFFECTS OF TETRAHYDROCANNABINOL CONTENT ON MARIJUANA SMOKING-BEHAVIOR, SUBJECTIVE REPORTS, AND PERFORMANCE [J].
HEISHMAN, SJ ;
STITZER, ML ;
YINGLING, JE .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1989, 34 (01) :173-179